SCHEMBL5214070

SCHEMBL5214070

Cc1ccc(C(=O)O)c(NC(=O)Cc2c[nH]c3ccc(OCc4ccccc4)cc23)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.57
PPARD Q03181 1/20 0.57
PPARA Q07869 1/20 0.57
TRPM8 Q7Z2W7 3/20 0.54
LTA4H P09960 6/20 0.52
PLA2G2A P14555 6/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52
HTR1D P28221 3/20 0.50
POLB P06746 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
SIRT2 Q8IXJ6 1/20 0.49
SLC6A4 P31645 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
MDH2 P40926 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5207887 0.87 KDM4E (0.60) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL5210851 0.83 MAPT (0.60) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL5211955 0.82 LTA4H (0.48) TRPM8LTA4HPLA2G2AMEN1KMT2A
SCHEMBL5209045 0.81 CDK2 (0.49) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL5210504 0.81 TSHR (0.56) POLBKDM4EMAPTSLC6A4SMN1; SMN2
SCHEMBL5207800 0.79 ICMT (0.51) MEN1KMT2AKDM4E
SCHEMBL5213599 0.79 ICMT (0.61) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL853597 0.78 LTA4H (0.64) PPARGPPARDPPARATRPM8LTA4H
SCHEMBL30176255 0.78 LTA4H (0.64) PPARGPPARDPPARATRPM8LTA4H
SCHEMBL4490807 0.78 PPARG (0.71) PPARGPPARDPPARATRPM8LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 US claimed
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 US disclosed
EP-1343757-B1 INDOLE DERIVATIVES GLAXO GROUP LTD (GB) 2007-02-14 EP disclosed
US-20040092569-A1 Indole derivatives GLAXO GROUP LIMITED (GB) 2004-05-13 US disclosed
EP-1343757-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-09-17 EP disclosed
WO-2002050031-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092569-A1 Indole derivatives PTGER4, PTGER1, TRPV4 PPARG 1182/4885PPARD 876/4885PPARA 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.